FDA Inspection
Ipsen BioPharm LtdIpsen BioPharm Ltd – FDA Inspection, Sep 12, 2017
Record Details
This FDA Inspection record concerns Ipsen BioPharm Ltd, with an inspection on September 12, 2017, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · 997abaeb-150c-4efd-9606-322cf0210140
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1026364
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
FDA Citations
5- 21 CFR 211.68(b)Computer control of master formula records
- 21 CFR 211.192Extent of discrepancy, failure investigations
- 21 CFR 211.160(b)Scientifically sound laboratory controls
- 21 CFR 211.113(b)Procedures for sterile drug products
- 21 CFR 211.100(a)Approval and review of procedures
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Ipsen BioPharm Ltd
7| Date | Classification | Office | Project area |
|---|---|---|---|
| May 22, 2025 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| April 26, 2019 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| July 6, 2018 | VAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
| January 20, 2016 | VAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
| July 8, 2014 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Ipsen BioPharm Ltd
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.